• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Formulary decision making might require some guidance


Seattle—With pharmaceutical costs being the fastest increasing component of healthcare costs, it is important that managed care executives adopt policies that use the best-available evidence to compare the benefits, risks and costs of drugs to include in their health plan formularies.

"Most health plans already devote significant attention and resources to formulary decisions," says Greg Simon, MD, MPH, a researcher at Group Health Cooperative. "It is our hope that formulary committees and other decision makers focus on important questions and ask for the right kinds of evidence."

According to Dr. Simon, the most important principles that MCOs can use to guide decisions that improve patient safety and lower costs include:

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.